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Abstract 
Objective 
To validate STOPPFrail, a list of explicit criteria for potentially inappropriate medication (PIM) use in 
frail older adults with limited life expectancy. 
Design 
A Delphi consensus survey of an expert panel comprising academic geriatricians, clinical 
pharmacologists, palliative care physicians, old age psychiatrists, general practitioners and clinical 
pharmacists. 
Setting 
Ireland. 
Subjects 
Seventeen panellists. 
Methods 
STOPPFrail criteria were initially created by the authors based on clinical experience and literature 
appraisal. Criteria were organised according to physiological system; each criterion accompanied by 
an explanation. Using Delphi consensus methodology, panellists ranked their agreement with each 
criterion on a 5-point Likert scale and provided written feedback. Criteria with a median Likert 
response of 4/5 (agree/strongly agree) and a 25th centile of ≥4 were included in the final list.  
Results 
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All panellists completed 3 Delphi rounds. Thirty criteria were proposed; 27 were accepted. The first 
two criteria suggest deprescribing medications without indication or where compliance is poor. The 
remaining 25 criteria include lipid-lowering therapies, alpha-blockers for hypertension, anti-
platelets, neuroleptics, memantine, proton-pump-inhibitors, H2-receptor antagonists, anti-
spasmodic agents, theophylline, leukotriene antagonists, calcium supplements, bone anti-resorptive 
therapy, selective oestrogen receptor modulators, non-steroidal anti-inflammatories, 
corticosteroids, 5-alpha-reductase inhibitors, alpha-1-selective blockers, muscarinic antagonists, oral 
diabetic agents, ACE-inhibitors, angiotensin receptor blockers, systemic oestrogens, multivitamins, 
nutritional supplements and prophylactic antibiotics. Consensus could not be reached on the 
inclusion of acetyl-cholinesterase inhibitors. Full consensus was reached on exclusion of 
anticoagulants and anti-depressants from the list. 
Conclusion 
STOPPFrail comprises 27 criteria relating to medications that are potentially inappropriate in frail 
older patients with limited life expectancy. STOPPFrail may assist physicians in deprescribing 
medications in these patients. 
Keywords  
Frail, life expectancy, deprescribing, polypharmacy, explicit criteria 
Key points 
STOPPFrail comprises 27 criteria for potentially inappropriate medications in frail older adults with 
limited life expectancy. 
STOPPFrail may serve to assist physicians in deprescribing medications in a structured fashion in this 
group.  
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STOPPFrail can be applied in frail older adults with limited life expectancy in any healthcare setting. 
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Introduction 
Population demographics are changing globally, with the greatest proportional increases 
seen in those aged ≥70 years [1]. Many older people are surviving longer with complex co-morbid 
illnesses including dementia, chronic kidney disease, cardiovascular disease, chronic lung disease 
and cancer, many of which contribute to frailty and poor survival prognosis [2, 3]. Chronic illnesses 
coupled with normal physiological ageing can have a negative impact on cognition and functional 
ability. In such patients, the final months of life are often characterised by frailty and increased 
dependency thus requiring re-evaluation of treatment goals, particularly medications intended to 
have long-term preventative effects such as lipid lowering drugs, anti-diabetic agents and cognitive 
enhancing drugs.  
Nursing home residents are usually frail, with high levels of functional dependency, multiple 
co-morbid illnesses and high levels of medication use [4, 5]. In Ireland, 6% of adults aged ≥65 years 
live in nursing homes, increasing to 12% in those 80 to 84 years and 25% in those over 85 years [6]. 
In the United States [US], similar figures are seen with approximately 5% of adults’ ≥67 years living in 
institutional care [7]. These proportions are likely to increase with current demographic trends. 
Currently, the median length of time from nursing home admission to death in the US is five months 
and within 1 year of admission, 65% of residents have died [8]. Clearly, the majority of older patients 
requiring admission to nursing homes have a limited life expectancy compared to those residing in 
the community. However, this frail group represents some of the highest consumers of prescription 
medications, despite a clearly reduced likelihood of long-term clinical benefit. The SHELTER study 
reports the rate of polypharmacy (5 – 9 drugs) and excessive polypharmacy (≥10 drugs) in nursing 
home residents to be 48.7% and 24.3% respectively [9].  
Inappropriate prescribing (IP) is also prevalent in older adults. IP pertains to the mis-
prescribing, overprescribing and under prescribing of medications in the context of a person’s co-
morbidities, full medication regime, functional and cognitive status as well as treatment goals and 
life expectancy [10]. In one US study of nursing home residents with dementia, more than half 
6 
 
received at least one daily drug of questionable benefit [11]. Polypharmacy and IP in older adults are 
linked to adverse drug events (ADEs), which can have a negative impact particularly on frail, multi-
morbid nursing home residents [12]  
Despite the high prevalence rates of polypharmacy and IP in the nursing home population, 
there is a paucity of evidence regarding the deprescribing of medications in older frail people with 
poor survival prognosis. Deprescribing refers to the process of tapering or stopping medications, 
aimed at reducing polypharmacy and improving patient outcomes. Although healthcare 
professionals, patients and their relatives all acknowledge the burden of polypharmacy for older 
people including administration time, adverse effects and cost, all groups display passivity towards 
deprescribing [13]. General Practitioners (GPs) cite many challenges to deprescribing including 
organisational factors, suboptimal medical and pharmacy records, limited time and limited training 
of nursing staff. Consequently, less than half use a consistent approach to deprescribing [14]. The 
National Institute for health and Care Excellence (NICE) recommend annual medication reviews in 
care home residents, during which appropriateness of medications should be optimised including 
deprescribing where necessary [15]. For community dwelling older adults with chronic diseases, no 
time frame is suggested [16, 17].  
Although frailty is sometimes difficult to define, it is common in later life and increases with 
age [18]. Over 50% of nursing home residents [4] and 17% of community dwelling older adults are 
considered frail [19]. In the United Kingdom (UK) 14% of hospital admissions have at least one frailty 
syndrome [20]. Not all patients who are frail have a limited life expectancy, however, numerous 
studies link frailty to worsening disability, hospitalisation and death [21]. In patients with frailty and 
limited life expectancy, medication review should primarily focus on deprescribing and symptom 
management, rather than aggressive preventative strategies. 
Numerous explicit prescribing tools aim to guide clinicians on cessation of PIMs including 
Beers [22], STOPP/START [23] and FORTA criteria [24]. STOPP/START criteria have been shown to 
improve medication appropriateness [25, 26] and reduce the incidence of adverse drug reactions 
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(ADRs) in hospitalised older adults [27]. However, these comprehensive tools are designed to detect 
common and preventable PIMs in the general older population and not specifically in frailer people 
with limited life expectancy. Indeed, STOPP/START criteria have limited applicability in this cohort. 
For instance patients with limited life expectancy would be unlikely to survive long enough to derive 
benefit from most medication listed in the START criteria. Furthermore, STOPP criteria do not 
suggest discontinuing major drugs classes that are least likely to have benefits in the last year of life 
e.g. statins. Therefore, with the accepted need for deprescribing in the frail older population, there 
is a clear associated need for specific explicit criteria to guide the prescriber. To date, no explicit 
guidelines exist for deprescribing in frailer older people with limited life expectancy, other than 
NORGEP-NH criteria, which are specific to the nursing home population [28].  
We aimed to develop an explicit tool, called STOPPFrail, to assist clinicians with 
deprescribing medications in frailer older adults with limited life expectancy in all healthcare 
settings.  
 
Methods 
Draft STOPPFrail criteria 
The authors, all of whom have recognised expertise in geriatric pharmacotherapy, compiled 
the initial draft of STOPPFrail indicators and arranged them according to physiological systems, 
similar to STOPP/START criteria. We then identified the target for whom these criteria would be 
applicable i.e. (i) end-stage irreversible pathology, (ii) poor one year survival prognosis, (iii) severe 
physical functional impairment or cognitive impairment of both, (iv) symptom control is the priority 
rather than prevention of disease. Since the most consistent predictors of mortality are co-
morbidities and functional impairment [29], our definition of patients who are appropriate for 
deprescribing according to STOPPFrail criteria was based on these essential indicators, rather than 
the presence of specific diseases, such as dementia or cancer. Also Incorporated in the tool are 
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challenges associated with medication use in this population, such as administration time and 
physical discomfort, as these have been reported by healthcare professionals, patients and their 
families to be of concern [13].  
Following this, the evidence base for each drug or drug class was checked using the British 
National Formulary and an extensive literature review, limited to the last 20 years. Literature 
searches of PubMed, Cinahl and Google Scholar were undertaken. Searches included the drug in 
question with key words such as “life expectancy”, “frailty”, “older adults”, “poor prognosis”, 
“deprescribing”, “inappropriate prescribing” and “adverse drug events”. The draft criteria were 
agreed on a consensus basis by the authors and subsequently distributed to a panel of experts for 
validation by the Delphi technique [30], an established method for achieving consensus. The Delphi 
method was used for this research because of the lack of rigorous randomised controlled evidence 
supporting the long term benefits of preventive drugs in frailer older adults with complex co-
morbidities and limited life expectancy; such patients are commonly excluded from clinical trials of 
drug therapies [31].  
Expert panel selection 
In June 2015, twenty five experts, were invited to participate in the Delphi process. Panellists 
were selected on the basis of their recognised academic credentials, clinical practice, experience and 
geographical diversity. After the study design and aims were explained to each participant, 
seventeen agreed to participate. The panel consisted of consultant geriatricians [n=6], clinical 
pharmacologists [n=3], old age psychiatrists [n=1], palliative care physicians [n=3], as well as senior 
academic primary care physicians [n=2] and clinical pharmacists with an interest in geriatric 
pharmacotherapy [n=2]. All of the panellists were affiliated with Irish university teaching hospitals 
(two in Northern Ireland). The panel was provided with an electronic repository containing 
supporting references for the proposed STOPPFrail criteria. Panellists’ competed the Delphi process 
between July 2015 and February 2016. 
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Data Collection and Analysis 
Each round was sent to the panellists using an online survey [SurveyMonkey®]. The first 
Delphi round consisted of 30 criteria. Each criterion was presented in the same format i.e. a drug or 
drug class deemed potentially inappropriate followed by an explanatory sentence. Panellists rated 
their agreement with each statement on a 5-point Likert scale, where 5 = strongly agree, 4 = agree, 3 
= neutral, 2 = disagree, 1 = strongly disagree, 0 = unable to offer an opinion [32]. In round 1, 
panellists were also asked to offer suggestions or comments (including new drugs) as appropriate. 
Statistical analysis 
For each statement, consensus was based on the median Likert response and interquartile 
range. A median value of 4 or 5 with a 25th centile of ≥4 was accepted for inclusion in the tool i.e. 
only statements with at least 75% of respondents agreeing or strongly agreeing were included. 
Proposed criteria with a median value of ≤3 were rejected: those with a median value of 4 or 5 and a 
25th centile of < 4 were rephrased in accordance with panellists’ suggestions and included in the next 
Delphi round. Statistical analysis was performed using IBM SPSS® Statistics version 22. 
Results 
All panellists completed the Delphi validation process in three rounds (Figure 1); 27 criteria 
comprise the final STOPPFrail tool (Table 1). Full statistical analysis (i.e. the phrasing of criteria and 
the distribution of the responses for each round) is available in supplementary data  
In round 1, twenty criteria were accepted. The first proposed criterion included in 
STOPPFrail was a general statement that any drug prescribed without a clinical indication should be 
discontinued. The remaining 19 criteria accepted included lipid-lowering agents, alpha-blockers for 
hypertension, neuroleptics, proton pump inhibitors, theophyllines, leukotriene receptor antagonists, 
selective estrogen receptor modulators, non-steroidal anti-inflammatories, steroids, 5-alpha 
reductase inhibitors and alpha-blockers in catheterised patients, muscarinic antagonists, diabetic 
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oral agents, Angiotension-converting-enzyme inhibitors, Angiotensin receptor antagonists, 
multivitamins and nutritional supplements.  
Two criteria were rejected in round 1. The first was the prescription of anticoagulants as a 
preventative measure. Our research group proposed discontinuation of as we considered that the 
bleeding risk and cost of treating outweighed the potential benefits to patients in whom cognition 
and function were poor.  Panellists agreed that in the majority of people meeting the criteria for 
STOPPFrail, anticoagulants should be stopped, however this criterion was rejected due to their 
concern over the minority of patients in whom stopping anticoagulants would be potentially 
inappropriate. Specifically, the majority considered that, regardless of frailty and life expectancy, 
stroke was an unfavourable outcome. Both panellists and the authors agreed that individual clinical 
judgement should be applied based on individual preferences and priorities with regards to anti-
coagulation. In recent years, anticoagulation has become easier, safer and more efficient due to 
novel anticoagulant drugs. Therefore panellists felt that in patients receiving anti-coagulants with 
minimal side effects, continuation was warranted.  
The second criterion rejected in round 1 was the use of anti-depressants in patients with 
advanced dementia. Reasons for rejection included possible benefits outside anti-depressant effects 
such as analgesic effects, appetite stimulation and anxiolytic properties. Feedback suggested that 
cessation in patients with severe dementia was a reasonable approach, but not in all patients with 
limited life expectancy. Panellists feared that antidepressant therapy could be stopped in patients 
who derived benefit from treatment and that the risk of relapse outweighed the potential benefit of 
discontinuation. 
Eight criteria were deemed inconclusive after round 1. The first was a general criterion of 
deprescribing any drug with which patients fail to comply. Feedback suggested that the explanatory 
sentence should remind users to try all appropriate measures to improve compliance before 
deprescribing; this criterion was rephrased accordingly for round 2. Other drugs for which there was 
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uncertainty among the panel were anti-platelets, memantine, acetylcholinesterase inhibitors, H2-
receptor antagonists, calcium and vitamin D supplements, bone anti-resorptive/anabolic agents and 
prophylactic antibiotics.  Feedback was incorporated into rephrasing the criteria for round 2.  
Panellists agreed with the inclusion of anti-platelet agents, but raised concerns over their 
cessation when their indication was secondary prevention. Similar to the feedback for anti-
coagulation, panellists were concerned about the minority of patients were deprescribing may be 
inappropriate. It was felt that secondary prevention should incorporate specialist judgement, and 
that a generalised statement would not be appropriate. Hence it was decided that primary 
prevention should be the focus of this criterion. Panellists welcomed the inclusion of calcium 
supplementation and anti-resorptive therapy in STOPPFrail, but asked for clarity around the 
explanatory sentence i.e. cessation where the indication was osteoporosis and not malignancy. 
Evidence is lacking on whether long term use of calcium is beneficial due to methodological flaws in 
studies and high dropout rates [33]. Patient compliance with calcium supplements is poor; those 
most likely to be non-compliant have a history of smoking, poor mobility and previous fractures [34]. 
Anti-resorptive medications are challenging to administer, have a less favourable side effect profile 
and in some cases have been shown to continue to have clinical benefits after cessation e.g. 
bisphosphonates. For these reasons the panellists agreed to cessation in those with limited life 
expectancy, 
Consensus could not be reached on two criteria after round 2 i.e. cessation of (i) memantine 
and (ii) acetylcholinesterase inhibitors in advanced dementia. A third Delphi round was therefore 
prepared for circulation. In this round, consensus was obtained for memantine and it was included in 
the STOPPFrail tool. Consensus was not achieved for acetylcholinesterase inhibitors with no trend 
towards acceptance (Table 2). Panellists reported that the evidence base for acetylcholinesterase 
inhibitors in advanced dementia was still developing and the possibility that unrecognised benefits 
existed could not be dismissed. The DOMINO-AD trial was cited to support their exclusion [35, 36].  
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This trial suggests that in patients where acetylcholinesterase inhibitors are stopped, the admission 
rate to nursing homes in the following year is increased compared to those who continue 
acetylcholinesterase inhibitors. However, this difference is only seen in the first year following 
cessation. After three rounds, no additional concerns were raised by the panel and it was decided by 
the authors not to proceed to thus a fourth Delphi round was deemed unnecessary. 
The final consensus STOPPFrail criteria are presented in table 1. An explanatory sentence to 
aid the decision to deprescribe the medication in question is present for clarification purposes, 
particularly to guide deprescribing drugs which cannot be stopped abruptly i.e. neuroleptics and 
long term steroids.  
Discussion  
STOPPFrail is an explicit list of 27 PIMs in frail older adults with limited life expectancy. The 
criteria are not designed to replace clinical judgement, but rather to assist clinicians with medication 
reviews and assessment of treatment goals in this specific patient cohort. Recognition of those 
patients to whom STOPPFrail is applicable may be challenging for less experienced physicians; in 
these circumstances, the use of simple mortality predictive tools may be helpful to guide life 
expectancy e.g. the Walter Index [37] or the CIRS-geriatric scale [38]. However, we anticipate that 
the majority of clinicians who will use this tool will be experienced in recognising patients who are 
appropriate for its application i.e. general practitioners or senior hospital specialists with prognostic 
knowledge of the diseases they manage. In the interest of simplicity and for the tool to be user 
friendly we did not want STOPPFrail to be contingent on the use of another tool to determine 
eligibility. 
Polypharmacy is a well described problem in this cohort. This research aims to put a 
framework on the guiding principle of deprescribing in late life i.e. that the benefits of many 
preventive medications are negligible in those with a limited life expectancy. Although many IP 
explicit tools exist, there has been an unmet need for a concise explicit tool to assist deprescribing in 
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this specific patient cohort. STOPPFrail is short tool, focusing on 27 key indicators, suggesting that it 
will be easy to use, time efficient and therefore more likely to be implemented. Like STOPP/START 
criteria [23], STOPPFrail criteria are listed according to physiological system, thereby allowing users 
to structure their approach to deprescribing. We aimed for a concise set of criteria that can be easily 
deployed in paper and electronic format.  Electronic application medication assessment criteria is 
challenging and the discussion of their potential benefits and implementation is beyond the scope of 
this paper. However, electronic implementation of the STOPP/START criteria is the focus of the 
SENATOR clinical trial (39), currently recruiting patients, and similarly there is the potential for the 
electronic implementation of STOPPFrail criteria. 
Developing this tool required discussing many controversial treatments e.g. hypertension. 
The authors and panellists agreed that a generalised statement about discontinuing all anti-
hypertensives would be contentious. Therefore, it was decided to focus on the drug class least likely 
to be prescribed as a first line agent and most likely to cause orthostatic hypotension and falls in an 
older cohort i.e. alpha-blockers. 
Inevitably, explicit STOPPFrail criteria will be compared with implicit deprescribing criteria 
designed for use in older populations, such as the Garfinkel algorithm [40] and the CEASE criteria 
[41, 42], which have small-scale clinical trial evidence to support their efficacy. Despite this evidence, 
implicit criteria for prescribing and deprescribing have not come into routine clinical practice. It 
remains to be seen whether STOPPFrail, as the first systematic set of explicit deprescribing criteria 
designed specifically for older people with advanced frailty and poor survival prognosis, holds a 
greater likelihood of being applied in the routine clinical situation than implicit criteria sets. 
Finally appropriate use of STOPPFrail criteria may have pharmaco-economic benefits. Older 
frail adults with a poor survival prognosis account for a growing proportion of the population and a 
disproportionately high level of medication consumption. Implementation of safe, evidence-based 
deprescribing in this population, may improve patients’ quality of life through reduced ADEs, related 
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hospitalisations and mortality. The true value of STOPPFrail will need to be tested by means of 
randomised controlled trials examining its impact as an intervention on patient quality of life, 
healthcare utilization, medication costs and mortality.  
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Table 1: Final STOPPFrail criteria 
STOPP frail is a list of potentially inappropriate prescribing indicators designed to assist physicians with stopping such 
medications in older patients [≥ 65 years] who meet ALL of the criteria listed below: 
 
1. End-stage irreversible pathology 
2. Poor one year survival prognosis 
3. Severe functional impairment or severe cognitive impairment or both 
4. Symptom control is the priority rather than prevention of disease progression 
 
The decision to prescribe/not prescribe medications to the patient, should also be influenced by the following issues: 
 
1. Risk of the medication outweighing the benefit 
2. Administration of the medication is challenging 
3. Monitoring of the medication effect is challenging 
4. Drug adherence/compliance is difficult 
Section A: General 
A1: Any drug that the patient persistently fails to take or tolerate despite adequate education and consideration of all 
appropriate formulations. 
A2. Any drug without clear clinical indication. 
Section B: Cardiovascular system 
B1. Lipid lowering therapies [statins, ezetimibe, bile acid sequestrants, fibrates, nicotinic acid and acipimox] 
These medications need to be prescribed for a long duration to be of benefit. For short-term use, the risk of adverse drug 
events [ADEs] outweighs the potential benefits [43, 44, 45] 
B2. Alpha-blockers for hypertension 
Stringent blood pressure control is not required in very frail older people. Alpha blockers in particular can cause marked 
vasodilatation, which can result in marked postural hypotension, falls and injuries [46] 
Section C: Coagulation system 
C1: Anti-platelets 
Avoid anti-platelet agents for primary [as distinct from secondary] cardiovascular prevention [no evidence of benefit] [47] 
Section D: Central Nervous System 
D1. Neuroleptic antipsychotics 
Aim to reduce dose and gradually discontinue these drugs in patients taking them for longer than 12 weeks if there are no 
current clinical features of behavioural and psychiatric symptoms of dementia [BPSD] [48, 49, 50, 51, 52]  
D2: Memantine 
Discontinue and monitor in patients with moderate to severe dementia, unless memantine has clearly improved behavioural 
and psychological symptoms of dementia [BPSD] [specifically in frail patients who meet the criteria above] [53, 54, 55, 56] 
Section E: Gastrointestinal System 
E1. Proton Pump Inhibitors 
Proton Pump Inhibitors at full therapeutic dose ≥ 8/52, unless persistent dyspeptic symptoms at lower maintenance dose [57] 
E2: H2 receptor antagonist 
H2 receptor antagonist at full therapeutic dose for ≥ 8/52, unless persistent dyspeptic symptoms at lower maintenance dose 
[57] 
E3. Gastrointestinal antispasmodics 
Regular daily prescription of gastrointestinal antispasmodics agents unless the patient has frequent relapse of colic symptoms 
because of high risk of anti-cholinergic side effects [57] 
Section F: Respiratory System 
F1. Theophylline.  
This drug has a narrow therapeutic index, requires monitoring of serum levels and interacts with other commonly prescribed 
drugs putting patients at an increased risk of ADEs [58, 59, 60] 
F2. Leukotriene antagonists [Montelukast, Zafirlukast] 
These drugs have no proven role in COPD, they are indicated only in asthma [61] 
Section G: Musculoskeletal System 
G1: Calcium supplementation 
Unlikely to be of any benefit in the short term 
G2: Anti-resorptive/bone anabolic drugs FOR OSTEOPOROSIS [bisphosphonates, strontium, teriparatide, denosumab] 
Unlikely to be of any benefit in the short term 
G3. Selective Estrogen Receptor Modulators [SERMs] for osteoporosis 
Benefits unlikely to be achieved within 1 year, increased short-intermediate term risk of associated ADEs particularly 
venous thromboembolism and stroke [57] 
G4. Long-term oral NSAIDs 
 Increased risk of side effects [peptic ulcer disease, bleeding, worsening heart failure etc.] when taken regularly for ≥ 2 
months [62, 63, 64] 
G5. Long-term oral steroids 
Increased risk of side effects [peptic ulcer disease etc.] when taken regularly for ≥ 2 months. Consider careful dose 
reduction and gradual discontinuation [65] 
Section H: Urogenital System 
H1. 5-alpha reductase inhibitors 
No benefit with long term urinary bladder catheterisation [66, 67] 
H2. Alpha blockers 
No benefit with long term urinary bladder catheterisation [66, 67] 
H3. Muscarinic antagonists 
No benefit with long term urinary bladder catheterisation, unless clear history of painful detrusor hyperactivity [66, 67] 
Section I: Endocrine System 
I1. Diabetic oral agents 
Aim for monotherapy. Target of HbA1c <8%/64mmol/mol. Stringent glycaemic control is unnecessary [68] 
I2. ACE-Inhibitors for diabetes 
Stop where prescribed only for prevention and treatment of diabetic nephropathy. There is no clear benefit in older 
people with advanced frailty with poor survival prognosis [69] 
I3. Angiotensin Receptor Blockers [ARBs] 
Stop where prescribed only for prevention and treatment of diabetic nephropathy. There is no clear benefit in older 
people with advanced frailty with poor survival prognosis [69] 
I4. Systemic oestrogens for menopausal symptoms  
Increases risk of stroke and VTE disease. Discontinue and only consider recommencing if recurrence of symptoms [57] 
Section J: Miscellaneous 
J1. Multi-vitamin combination supplements 
Discontinue when prescribed for prophylaxis rather than treatment 
J2. Nutritional supplements [other than vitamins] 
Discontinue when prescribed for prophylaxis rather than treatment [70] 
J3: Prophylactic Antibiotics 
No firm evidence for prophylactic antibiotics to prevent recurrent cellulitis or UTIs [71, 72, 73] 
Disclaimer (STOPPFrail) 
Whilst every effort has been made to ensure that the potentially inappropriate prescribing criteria listed in STOPPFrail are accurate and evidence-based, it is emphasized that the final decision to avoid or initiate any drug referred to in these criteria rests entirely with the prescriber. It is also to be noted that the evidence base 
underlying certain criteria in STOPPFrail may change after the time of publication of these criteria. Therefore, it is advisable that prescribing decisions should take account of current published evidence in support of or against the use of drugs or drug classes described in STOPPFrail. 
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Table 2: Acetyl Cholinesterase Inhibitors Delphi Results 
 Acetyl Cholinesterase Inhibitor 
Round 1 Round 2 Round 3 
Median 4.000 4.000 4.000 
25th centile 3.250 3.000 3.250 
 
Figure 1: Flow chart of Delphi Process 
 
 
 
 
 
 
 
 
 
 
 
Final STOPPfrail criteria
27 criteria
Round 3 [2 criteria]
0 accepted 0 rejected
2 inconclusive after 3 
rounds despite inclusion 
of panel's suggestions
Round 2 [8 criteria]
6 accepted 0 rejected
2 prepared for round 3 
following the panel's 
suggestions
Round 1 [30 criteria]
20 accepted 2 rejected 8 prepared for round 2 following panel's suggestions
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Supplementary Data 
Table1: Round 1 results 
STOPP frail is a list of potentially inappropriate prescribing indicators designed to assist physicians with stopping such medications in older patients 
(≥ 65 years) who meet ALL of the criteria listed below: 
  
 End-stage irreversible pathology  
 Poor Prognosis  
 Severe functional impairment or severe cognitive impairment or both 
 Symptom control is the priority rather than prevention of disease progression 
 
The decision to prescribe/not prescribe medications to the patient, should also be influenced by the following issues:  
 
 Risk of the medication outweighing the benefit  
 Administration of the medication is challenging 
 Monitoring of the medication effect is challenging 
 Drug adherence/compliance is difficult 
 
Criteria sent to panel 
 
Median 25th 
centile 
75th 
Centile 
Outcome 
Section A: General 
 
A1. Any drug that the patient persistently fails to comply with for any reason 
 
A2. Any drug without clear clinical indication 
 
 
4.000 
 
5.000 
 
 
3.500 
 
5.000 
 
 
 
5.000 
 
5.000 
 
 
Inconclusive 
 
Accepted 
Section B: Cardiology System 
 
B1. Lipid lowering therapies (statins, ezetimibe, bile acid sequestrans, fibrates, nicotinic acid and acipimox) 
These medications need to be prescribed for a long duration to be of benefit. For short-term use, the risk of adverse 
drug events outweighs the potential benefits.  
 
B2. Alpha-blockers for hypertension  
Stringent blood pressure control is not required in very frail older people. Alpha blockers in particular can cause 
marked vasodilatation, which can result in marked postural hypotension, falls and injuries.  
 
 
 
5.000 
 
 
 
5.000 
 
 
 
 
4.000 
 
 
 
4.000 
 
 
 
5.000 
 
 
 
5.000 
 
 
 
Accepted 
 
 
 
Accepted 
25 
 
 
Section C: Coagulation System 
 
C1. Anticoagulants (warfarin/novel oral anticoagulants)  
Anticoagulation as a preventative measure (e.g. with atrial fibrillation) as distinct from treatment of acute venous 
thromboembolic (VTE) disease. 
 
C2. Anti-platelet agents  
No role for anti-platelet agents in primary cardiovascular prevention, only beneficial for secondary cardiovascular 
prevention, therefore discontinue unless there is a previous history of ischaemic heart disease, cerebrovascular 
disease or arterial stent insertion. 
 
 
 
 
3.000 
 
 
 
 
4.000 
 
 
 
 
 
2.000 
 
 
 
 
3.000 
 
 
 
4.000 
 
 
 
 
5.000 
 
 
 
Rejected 
 
 
 
 
Inconclusive 
Section D: Central Nervous System 
 
D1. Memantine  
Discontinue unless it has been prescribed for behavioural and psychological symptoms of dementia (BPSD) in 
patients with Alzheimers disease and has been shown to improve symptoms. 
 
D2. Acetylcholinesterase inhibitors  
There is no significant clinical benefit from continuation of these drugs in those with advanced Alzheimers disease 
(Mini-Mental State Examination score <10/30 and functionally dependent). No role in other dementia syndromes in 
the advanced stages. 
 
D3. Anti-depressants  
There is no proven role for anti-depressants in advanced dementia (MMSE <10/30 and functionally dependent). 
 
D4. Neuroleptic antipsychotics  
Aim to reduce dose and discontinue these drugs in patients taking them for longer than 12 weeks if there are no 
current clinical features of behavioural and psychiatric symptoms of dementia (BPSD). 
 
 
 
 
4.000 
 
 
 
4.000 
 
 
 
3.000 
 
 
5.000 
 
 
 
2.250 
 
 
 
3.250 
 
 
 
2.000 
 
 
4.000 
 
 
 
5.000 
 
 
 
5.000 
 
 
 
4.000 
 
 
5.000 
 
 
 
Inconclusive  
 
 
 
Inconclusive  
 
 
 
Rejected 
 
 
Accepted 
Section E: Gastrointestinal System 
 
E1. Proton Pump Inhibitors 
Proton Pump Inhibitors at full therapeutic dose ≥ 8/52, unless persistent dyspeptic symptoms at lower maintenance 
dose. 
 
 
 
 
4.000 
 
 
 
 
 
4.000 
 
 
 
 
 
5.000 
 
 
 
 
 
Accepted 
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E2. H2 Receptor Antagonists  
H2 Receptor Antagonists at full therapeutic dose for ≥ 8/52, unless persistent dyspeptic symptoms or symptoms 
reoccur after discontinuation. 
 
E3. Gastrointestinal antispasmodics 
Regular daily prescription of gastrointestinal antispasmodics agents unless the patient has frequent relapse of colic 
symptoms because of high risk of anti-cholinergic side effects. 
 
 
4.000 
 
 
 
4.000 
 
3.500 
 
 
 
4.000 
 
5.000 
 
 
 
5.000 
 
 
 
Inconclusive  
 
 
 
Accepted 
Section F: Respiratory System 
 
F1. Theophylline  
This drug has a narrow therapeutic index, requires monitoring of serum levels and interacts with other commonly 
prescribed drugs putting patients at an increased risk of adverse drug events (ADEs).  
 
F2. Leukotriene antagonists (Montelukast, Zafirlukast) 
These drugs have no proven role in COPD, they are indicated only in asthma. 
 
 
 
 
5.000 
 
 
 
5.000 
 
 
 
4.000 
 
 
 
4.000 
 
 
 
5.000 
 
 
 
5.000 
 
 
 
Accepted 
 
 
 
Accepted 
Section G: Musculoskeletal System  
 
G1. Calcium and vitamin D supplementation 
Unlikely to be of any benefit in the short term. 
 
G2. Anti-resorptive/bone anabolic drugs for osteoporosis (bisphosphonates, strontium, teriparatide, denosumab) 
Benefits unlikely to be achieved within 1 year, increased short-intermediate term risk of associated adverse drug 
events.  
 
G3. Selective Estrogen Receptor Modulators (SERMs) for osteoporosis 
Benefits unlikely to be achieved within 1 year, increased short-intermediate term risk of associated ADEs particularly 
venous thromboembolism and stroke. 
 
G4. Long-term oral NSAIDs  
Increased risk of side effects (peptic ulcer disease, bleeding, worsening heart failure etc.) when taken regularly for ≥ 
2 months.  
 
G5. Long-term oral steroids  
 
 
 
4.000 
 
 
4.000 
 
 
5.000 
 
 
 
5.000 
 
 
5.000 
 
 
 
3.000 
 
 
3.000 
 
 
4.000 
 
 
 
4.000 
 
 
4.000 
 
 
 
5.000 
 
 
5.000 
 
 
5.000 
 
 
 
5.000 
 
 
5.000 
 
 
 
Inconclusive  
 
 
Inconclusive 
 
 
Accepted 
 
 
 
Accepted 
 
 
Accepted 
27 
 
Increased risk of side effects (peptic ulcer disease etc.) when taken regularly for ≥ 2 months. Consider careful dose 
reduction and discontinuation. 
 
Section H: Urogenital System  
 
H1. 5-alpha reductase inhibitors  
No benefit with long term urinary bladder catheterisation. 
 
H2. Alpha blockers with urinary catheter 
No benefit with long term urinary bladder catheterisation.  
 
H3. Muscarinic antagonists  
No benefit with long term urinary bladder catheterisation, unless clear history of painful detrusor hyperactivity. 
 
 
 
 
5.000 
 
 
5.000 
 
 
5.000 
 
 
 
4.000 
 
 
4.000 
 
 
4.000 
 
 
 
5.000 
 
 
5.000 
 
 
5.000 
 
 
 
Accepted 
 
 
Accepted 
 
 
Accepted 
Section I: Endocrine System 
 
I1. Diabetic oral agents  
Aim for monotherapy. Target of HbA1c <8%/64mmol/mol. Stringent glycaemic control is unnecessary 
  
I2. ACE-Inhibitors for diabetes  
Stop where prescribed only for prevention and treatment of diabetic nephropathy. There is no clear benefit in older 
people with advanced frailty with poor survival prognosis.  
 
I3. Angiotensin Receptor Blockers (ARBs) 
Stop where prescribed only for prevention and treatment of diabetic nephropathy. There is no clear benefit in older 
people with advanced frailty with poor survival prognosis.  
 
I4. Systemic oestrogens for menopausal symptoms 
Increases risk of stroke and VTE disease. Discontinue and only consider recommencing if recurrence of  
Symptoms. 
 
 
 
 
4.000 
 
 
4.000 
 
 
 
4.000 
 
 
 
4.000 
 
 
 
4.000 
 
 
4.000 
 
 
 
4.000 
 
 
 
4.000 
 
 
 
4.500 
 
 
5.000 
 
 
 
5.000 
 
 
 
5.000 
 
 
 
Accepted 
 
 
Accepted 
 
 
 
Accepted 
 
 
 
Accepted  
Section J: Miscellaneous 
 
J1. Multi-vitamin combination supplements  
Discontinue when prescribed for prophylaxis rather than treatment. 
 
 
 
 
5.000 
 
 
 
 
4.000 
 
 
 
 
5.000 
 
 
 
 
Accepted 
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J2. Nutritional supplements (other than vitamins)  
Discontinue when prescribed for prophylaxis rather than treatment. 
 
J3. Prophylactic antibiotics  
No firm evidence for a role for prophylactic antibiotics for recurrent cellulitis or recurrent UTI. 
 
 
5.000 
 
 
4.000 
 
4.000 
 
 
3.000 
 
5.000 
 
 
5.000 
 
 
Accepted 
 
 
Inconclusive  
 
 
Round 2 Results 
STOPP frail is a list of potentially inappropriate prescribing indicators designed to assist physicians with stopping such medications in older patients 
(≥ 65 years) who meet ALL of the criteria listed below: 
  
 End-stage irreversible pathology  
 Poor Prognosis  
 Severe functional impairment or severe cognitive impairment or both 
 Symptom control is the priority rather than prevention of disease progression 
 
The decision to prescribe/not prescribe medications to the patient, should also be influenced by the following issues:  
 
 Risk of the medication outweighing the benefit  
 Administration of the medication is challenging 
 Monitoring of the medication effect is challenging 
 Drug adherence/compliance is difficult 
 
Criteria sent to panel 
 
Median 25th 
centile 
75th 
centile 
Outcome 
Section A: General 
 
A1. Any drug that the patient persistently fails to take or tolerate despite adequate education and consideration of 
all appropriate formulations 
 
 
 
5.000 
 
 
4.000 
 
 
5.000 
 
 
 
Accepted 
Section C: Coagulation System 
 
C2. Anti-platelet agents  
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Avoid anti-platelet agents for primary (as distinct from secondary) cardiovascular prevention (no evidence of 
benefit). 
 
5.000 4.000 5.000 Accepted 
Section D: Central Nervous System 
 
D1. Memantine  
Discontinue and monitor in patients with moderate to severe dementia, unless memantine has clearly improved 
BPSD. 
 
D2. Acetylcholinesterase inhibitors  
Discontinue and monitor in patients with severe dementia. 
 
 
 
 
4.000 
 
 
4.000 
 
 
 
3.500 
 
 
3.000 
 
 
 
5.000 
 
 
5.000 
 
 
 
Inconclusive 
 
 
Inconclusive 
Section E: Gastrointestinal System 
 
E2. H2 Receptor Antagonists  
H2 Receptor Antagonists at full therapeutic dose for ≥ 8/52, unless persistent dyspeptic symptoms at lower 
maintenance dose. 
 
 
 
 
4.000 
 
 
 
4.000 
 
 
 
5.000 
 
 
 
 
Accepted 
Section G: Musculoskeletal System 
 
G1. Calcium supplementation 
Unlikely to be of any benefit in the short term 
 
G2. Anti-resorptive/bone anabolic drugs FOR OSTEOPOROSIS (bisphosphonates, strontium, teriparatide, 
denosumab)  
 
 
 
 
5.000 
 
4.000 
 
 
 
4.000 
 
4.000 
 
 
 
5.000 
 
5.000 
 
 
 
Accepted 
 
Accepted 
Section J: Miscellaneous 
 
J3. Prophylactic antibiotics  
No firm evidence for prophylactic antibiotics to prevent recurrent cellulitis or UTI. 
 
 
 
 
4.000 
 
 
 
4.000 
 
 
 
5.000 
 
 
 
Accepted 
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Round 3 Results 
STOPP frail is a list of potentially inappropriate prescribing indicators designed to assist physicians with stopping such medications in older patients (≥ 65 
years) who meet ALL of the criteria listed below: 
  
 End-stage irreversible pathology  
 Poor Prognosis  
 Severe functional impairment or severe cognitive impairment or both 
 Symptom control is the priority rather than prevention of disease progression 
 
The decision to prescribe/not prescribe medications to the patient, should also be influenced by the following issues:  
 
 Risk of the medication outweighing the benefit  
 Administration of the medication is challenging 
 Monitoring of the medication effect is challenging 
 Drug adherence/compliance is difficult 
 
Criteria sent to Panel Median 25th 
centile 
75th 
centile 
Outcome 
Section D: Central Nervous System 
 
D1: Memantine 
Discontinue and monitor in patients with moderate to severe dementia, unless memantine has clearly improved 
behavioural and psychological symptoms of dementia (BPSD) (specifically in frail patients who meet the criteria above) 
 
D2. Acetylcholinesterase inhibitors 
 Discontinue and monitor in patients with severe dementia (specifically in frail patients who meet the criteria above) 
 
 
 
 
4.000 
 
 
 
4.000 
 
 
 
4.000 
 
 
 
3.250 
 
 
 
5.000 
 
 
 
5.000 
 
 
 
Accepted 
 
 
 
Inconclusive 
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